As the awardee of the QuickFire Challenge, PExA will receive $250,000 in grant funding, mentorship and coaching from experts at Johnson & Johnson Innovation, the LCI and Janssen Research & Development, LLC, and access to the Johnson & Johnson Innovation - JLABS global entrepreneurial community.

The Challenge invited innovators from across the world to develop tools to better quantify the damage known to play a role in carcinogenesis resulting from exposure to tobacco smoke with the goal of reducing tobacco use by motivating smokers to quit. PExA, which focuses on the development and commercialization of a technology that allows researchers to non-invasively collect proximal biomarkers for lung diseases, was evaluated based on:

• Potential to impact healthcare outcomes in a strategic area of interest
• Uniqueness of solution & level of competition in current market
• Quality & feasibility of technology
• Team credibility & capabilities
• Clarity of plan: Milestones & defined go/no go decisions

Erik Ekbo, CEO at PExA:
- We are extremely proud and excited to be appointed the awardee in this global challenge by companies committed to improving health and notably in lung cancer, one of the most devastating diseases globally. This recognition will enable us to accelerate the realization of solutions for lung cancer prevention.

For further information about the Carcinogenic Exposure Meter QuickFire Challenge, see following webpage: https://jlabs.jnjinnovation.com/quickfire-challenges/carcinogenic-exposure-meter-quickfire-challenge

For further information, please contact:
Erik Ekbo, CEO
Phone: +46 723-92 30 30
E-mail: erik@pexa.se

This information is information which PExA AB is obligated to publish under the EU Market Abuse Regulation. The information was provided through the agency of above contact person, for publication on Februay 6, 2019.

PExA AB (556956-9246) develops and markets a research instrument with associated products and services to lung researchers for simple and non-invasive sampling, in order to study respiratory diseases such as asthma and chronic obstructive pulmonary disease, COPD. Sampling with PExA can be used to detect lung diseases at an early stage. The sample can be likened to a “blood test for the small airways”. The aim is to facilitate the development of reliable and more individualised diagnosis, monitoring and treatment of respiratory diseases. The original idea and research behind the method comes from the unit for Occupational and Environmental Medicine at the Sahlgrenska Academy at Gothenburg University. Commercial operations started in 2010 with the support of GU Ventures incubator, and the company is founded by inventors, key employees, business angels and GU Ventures. PExA’s B share is listed on Spotlight Stock Market